NEW YORK, July 23, 2018 /PRNewswire/ --
If you want a free Stock Review on TCDA, ZTS, ADMS,
and AGN sign up now at
https://stocktraderreport.com/registration/. On Friday, key US
indices were bearish as the NASDAQ Composite finished the trading
session down 0.07%; the Dow Jones Industrial Average edged 0.03%
lower; and the S&P 500 was down 0.09%. Before the US markets
open this morning, StockTraderReport.com appraises these four Drugs
- Generic equities: Tricida Inc. (NASDAQ: TCDA), Zoetis Inc. (NYSE:
ZTS), Adamas Pharmaceuticals Inc. (NASDAQ: ADMS), and Allergan PLC
(NYSE: AGN). All you have to do is sign up today for this free
limited time offer by clicking the link below.
https://stocktraderreport.com/registration/
Tricida
USA-headquartered Tricida
Inc.'s stock finished Friday's session 1.30% lower at $29.50. A total volume of 75,954 shares was
traded. The stock has advanced 13.46% on an YTD basis. Shares of
the Company, which focuses on developing therapeutics to address
renal, metabolic, and cardiovascular disease, are trading below its
50-day and 200-day moving averages by 2.64% and 2.64%,
respectively.
On July 02nd, 2018,
Tricida announced the closing of its initial public offering of
13,455,000 shares of its common stock, which includes the exercise
in full by the underwriters of their option to purchase up to
1,755,000 shares of common stock for total gross proceeds of
approximately $255.6 million, before
deducting underwriting discounts and commissions and other offering
expenses payable by the Company. The shares began trading on The
NASDAQ Global Select Market on June
28th, 2018 under the symbol "TCDA". Get the full
research report on TCDA for free by clicking below at:
https://stocktraderreport.com/registration/?symbol=TCDA
Zoetis
Shares in USA-based Zoetis Inc. ended at $85.29, down 0.15% from the last trading session.
The stock recorded a trading volume of 1.98 million shares. The
Company's shares have gained 35.92% in the last twelve months and
18.39% on an YTD basis. Shares of the Company, which discovers,
develops, manufactures, and markets veterinary vaccines and
medicines in the US and internationally, are trading above its
200-day moving average by 9.43%. Moreover, shares of Zoetis have an
RSI of 48.25 and have a dividend yield of 0.59%.
On June 29th, 2018,
Zoetis announced that it will host a webcast and conference call on
August 02nd, 2018, at
8:30 a.m. ET. CEO, Juan Ramón Alaix,
and Executive Vice President and CFO, Glenn
David, will review the Company's Q2 2018 financial results
and respond to questions from financial analysts during the call.
To experience our free membership services anytime/ anywhere and
access the free report on ZTS, click to register at:
https://stocktraderreport.com/registration/?symbol=ZTS
Adamas Pharmaceuticals
USA-based Adamas
Pharmaceuticals Inc.'s stock ended last Friday's session 0.15%
lower at $27.09 with a total trading
volume of 356,488 shares. The Company's shares have advanced 53.75%
in the last twelve months. The stock is trading below its 50-day
moving average by 2.24%. Additionally, shares of Adamas Pharma,
which discovers, develops, and sells therapies for chronic
neurologic disorders, have an RSI of 54.04.
On July 09th, 2018,
Adamas Pharma announced that the compensation committee of its
Board of Directors granted two new employees the option to purchase
an aggregate of 29,531 shares of its common stock, at a per share
exercise price of $25.74, the closing
trading price that day, and restricted stock units to acquire 4,921
shares of the common stock.
On July 16th, 2018,
research firm H.C. Wainwright initiated a 'Buy' rating on the
Company's stock, with a target price of $45 per share. Join our big investor community at
Stock Trader Report now and get your free report on ADMS at:
https://stocktraderreport.com/registration/?symbol=ADMS
Allergan
On Friday, shares in USA-headquartered Allergan PLC recorded a
trading volume of 1.50 million shares. The stock finished the day
0.92% lower at $171.79. The Company's
shares have advanced 8.38% in the previous three months. The stock
is trading above its 50-day and 200-day moving averages by 4.26%
and 1.46%, respectively. Furthermore, shares of Allergan, which
develops, manufactures, markets, and distributes medical
aesthetics, biosimilar, and over-the-counter pharmaceutical
products worldwide, have an RSI of 51.67 and have a dividend yield
of 1.68%.
On July 10th, 2018,
Allergan announced the launch of a new, over-the-counter artificial
tear formulation, REFRESH® REPAIR Lubricant Eye
Drops. REFRESH® REPAIR is the latest addition to
the REFRESH® portfolio and is the first and only
artificial tear in the US formulated with carboxymethylcellulose,
hyaluronic acid, and osmoprotectants. Know more about AGN in our
free research coverage at:
https://stocktraderreport.com/registration/?symbol=AGN
--
Stock Trader Report:
Stock Trader Report (STR) produces regular sponsored and
non-sponsored reports, articles, stock market blogs, and popular
investment newsletters covering equities listed on NYSE and NASDAQ
and micro-cap stocks. STR has two distinct and independent
departments. One department produces non-sponsored analyst
certified content generally in the form of press releases, articles
and reports covering equities listed on NYSE and NASDAQ and the
other produces sponsored content (in most cases not reviewed by a
registered analyst), which typically consists of compensated
investment newsletters, articles and reports covering listed stocks
and micro-caps. Such sponsored content is outside the scope of
procedures detailed below.
STR has not been compensated; directly or indirectly; for
producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by
a writer (the "Author") and is fact checked and reviewed by a
third-party research service company (the "Reviewer") represented
by a credentialed financial analyst [for further information on
analyst credentials, please email info@stocktraderreport.com.
Rohit Tuli, a CFA® charterholder
(the "Sponsor"), provides necessary guidance in preparing the
document templates. The Reviewer has reviewed and revised the
content, as necessary, based on publicly available information
which is believed to be reliable. Content is researched, written
and reviewed on a reasonable-effort basis. The Reviewer has not
performed any independent investigations or forensic audits to
validate the information herein. The Reviewer has only
independently reviewed the information provided by the Author
according to the procedures outlined by STR. STR is not entitled to
veto or interfere in the application of such procedures by the
third-party research service company to the articles, documents or
reports, as the case may be. Unless otherwise noted, any content
outside of this document has no association with the Author or the
Reviewer in any way.
NO WARRANTY
STR, the Author, and the Reviewer are not responsible for any
error which may be occasioned at the time of printing of this
document or any error, mistake or shortcoming. No liability is
accepted whatsoever for any direct, indirect or consequential loss
arising from the use of this document. STR, the Author, and the
Reviewer expressly disclaim any fiduciary responsibility or
liability for any consequences, financial or otherwise arising from
any reliance placed on the information in this document.
Additionally, STR, the Author, and the Reviewer do not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or
a solicitation of an offer to buy or sell the securities mentioned
or discussed, and is to be used for informational purposes only.
Please read all associated disclosures and disclaimers in full
before investing. Neither STR nor any party affiliated with us is a
registered investment adviser or broker-dealer with any agency or
in any jurisdiction whatsoever. To download our report(s), read our
disclosures, or for more information, visit
https://stocktraderreport.com/privacy-policy/
CONTACT
For any questions, inquiries, or comments reach out to us directly.
If you're a company, we are
covering and wish to no longer feature on our coverage list contact
us via email and/or phone between 09:30 EDT
to 16:00 EDT from Monday to Friday at:
Email: info@stocktraderreport.com
Phone number: 917-979-2038
Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
SOURCE Stock Trader Report